Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabo-POLARIS
2021-005549-34Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by CHU de Besançon. Primary endpoint: Rate of definitive cabozantinib discontinuation at 6 months. Started Dec 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2021-005549-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005549-34.